Warren Paula Province, Bebin E Martina, Nabors L Burt, Szaflarski Jerzy P
a Department of Neurology , University of Alabama at Birmingham , Birmingham , AL , USA.
Neurocase. 2017 Oct-Dec;23(5-6):287-291. doi: 10.1080/13554794.2017.1391294. Epub 2017 Oct 24.
Epilepsy, commonly encountered by patients with brain tumors, is often refractory to standard therapies. Our aim was to examine the safety and efficacy of pharmaceutical grade cannabidiol (CBD; Epidiolex; Greenwich Biosciences) in those patients with epilepsy with concomitant tumors enrolled in The University of Alabama at Birmingham CBD Program (NCT02700412 and NCT02695537). Of the three patients with refractory seizures and a history of a primary brain tumor, two had improvement in seizure frequency and all three had improvement in seizure severity. These pilot results suggest that CBD should be further studied for the treatment of brain tumor-related epilepsy.
癫痫在脑肿瘤患者中很常见，通常对标准治疗无效。我们的目的是研究药用级大麻二酚（CBD；Epidiolex；格林威治生物科学公司）对参加阿拉巴马大学伯明翰分校CBD项目（NCT02700412和NCT02695537）的伴有肿瘤的癫痫患者的安全性和有效性。在三名有难治性癫痫发作且有原发性脑肿瘤病史的患者中，两名患者的癫痫发作频率有所改善，三名患者的癫痫发作严重程度均有所改善。这些初步结果表明，应进一步研究CBD用于治疗脑肿瘤相关癫痫。
